<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Chinese Medicine - Most viewed articles</title>
		<link>http://www.cmjournal.orgmostviewed/</link>
		<description>Most viewed articles in last 30 days from Chinese Medicine (ISSN 1749-8546) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/4"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/7"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/6"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/2/1/6"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/1/1/4"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/2/1/11"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/2/1/5"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/3"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/5"/>			    
            
				    <rdf:li rdf:resource="http://www.cmjournal.org/content/3/1/8"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.cmjournal.org/content/3/1/4">
            
            <title>Chinese red yeast rice (Monascus purpureus-fermented rice) promotes bone formation</title>
			<description>Background:
Statin can induce the gene expression of bone morphogenetic protein-2. Red yeast rice (RYR, Hongqu), i.e. rice fermented with Monascus purpureus, contains a natural form of statin. This study demonstrates the effects of RYR extract on bone formation.
Methods:
Bone defects were created in the parietal bones of two New Zealand white rabbits. In the test animal, two defects were grafted with collagen matrix mixed with RYR extract. In the control animal, two defects were grafted with collagen matrix alone. UMR 106 cell line was used to test RYR extract in vitro. In the control group, cells were cultured for three durations (24 hours, 48 hours and 72 hours) without any intervention. In the RYR group, cells were cultured for the same durations with various concentrations of RYR extract (0.001 g/ml, 0.005 g/ml and 0.01 g/ml). Bicinchoninic acid (BCA) assay, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and alkaline phosphatase (ALP) assay were performed to measure total protein, mitochondrial activity and bone cell formation respectively.
Results:
The test animal showed more formation of new bone in the defects than the control animal. RYR significantly increased the optical density in the MTT assay and ALP activity in vitro.
Conclusion:
RYR extract stimulated new bone formation in bone defects in vivo and increased bone cell formation in vitro.</description>
			<link>http://www.cmjournal.org/content/3/1/4</link>		
			<dc:creator>Ricky WK Wong and Bakr Rabie</dc:creator>
			<dc:source>Chinese Medicine 2008, 3:4</dc:source>
			<dc:subject>Number of accesses: 808</dc:subject>
			<dc:date>2008-03-29</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-4</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/7">
            
            <title>Chemical markers for the quality control of herbal medicines: an overview</title>
			<description>Selection of chemical markers is crucial for the quality control of herbal medicines, including authentication of genuine species, harvesting the best quality raw materials, evaluation of post-harvesting handling, assessment of intermediates and finished products, and detection of harmful or toxic ingredients. Ideal chemical markers should be the therapeutic components of herbal medicines. However, for most herbal medicines, the therapeutic components have not been fully elucidated or easily monitored. Bioactive, characteristic, main, synergistic, correlative, toxic and general components may be selected. This article reviews the effective use of chemical markers in the quality control of herbal medicines including the selection criteria considering the roles and physicochemical factors which may affect the effective use of chemical markers.</description>
			<link>http://www.cmjournal.org/content/3/1/7</link>		
			<dc:creator>Songlin Li, Quanbin Han, Chunfeng Qiao, Jingzheng Song, Chuen Lung Cheng and Hongxi Xu</dc:creator>
			<dc:source>Chinese Medicine 2008, 3:7</dc:source>
			<dc:subject>Number of accesses: 772</dc:subject>
			<dc:date>2008-06-28</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-7</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/6">
            
            <title>An optimized high-performance liquid chromatography (HPLC) method for benzoylmesaconine determination in Radix Aconiti Lateralis Preparata (Fuzi, aconite roots) and its products</title>
			<description>Background:
Benzoylmesaconine (BMA) is the main Aconitum alkaloid in Radix Aconiti Lateralis Preparata (Fuzi, aconite roots) with potent pharmacological activities, such as analgesia and anti-inflammation. The present study developed a simple and reliable method using BMA as a marker compound for the quality control of processed aconite roots and their products.
Methods:
After extraction, a high-performance liquid chromatography (HPLC) determination of BMA was conducted on a RP-C18 column by gradient elution with acetonitrile and aqueous phase, containing 0.1% phosphoric acid adjusted with triethylamine to pH 3.0.
Results:
A distinct peak profile was obtained and separation of BMA was achieved. Method validation showed that the relative standard deviations (RSDs) of the precision of BMA in all intra-day and inter-day assays were less than 1.36%, and that the average recovery rate was 96.95%. Quantitative analysis of BMA showed that the content of BMA varied significantly in processed aconite roots and their products.
Conclusion:
This HPLC method using BMA as a marker compound is applicable to the quality control of processed aconite roots and their products.</description>
			<link>http://www.cmjournal.org/content/3/1/6</link>		
			<dc:creator>Ying Xie, Hua Zhou, Yuen Fan Wong, Zhongqiu Liu, Hongxi Xu, Zhihong Jiang and Liang Liu</dc:creator>
			<dc:source>Chinese Medicine 2008, 3:6</dc:source>
			<dc:subject>Number of accesses: 568</dc:subject>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-6</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/2/1/6">
            
            <title>Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides</title>
			<description>In Chinese medicine, ginseng (Panax ginseng C.A. Meyer) has long been used as a general tonic or an adaptogen to promote longevity and enhance bodily functions. It has also been claimed to be effective in combating stress, fatigue, oxidants, cancer and diabetes mellitus. Most of the pharmacological actions of ginseng are attributed to one type of its constituents, namely the ginsenosides. In this review, we focus on the recent advances in the study of ginsenosides on angiogenesis which is related to many pathological conditions including tumor progression and cardiovascular dysfunctions.         Angiogenesis in the human body is regulated by two sets of counteracting factors, angiogenic stimulators and inhibitors. The 'Yin and Yang' action of ginseng on angiomodulation was paralleled by the experimental data showing angiogenesis was indeed related to the compositional ratio between ginsenosides Rg1 and Rb1. Rg1 was later found to stimulate angiogenesis through augmenting the production of nitric oxide (NO) and vascular endothelial growth factor (VEGF). Mechanistic studies revealed that such responses were mediated through the PI3K&#8594;Akt pathway. By means of DNA microarray, a group of genes related to cell adhesion, migration and cytoskeleton were found to be up-regulated in endothelial cells. These gene products may interact in a hierarchical cascade pattern to modulate cell architectural dynamics which is concomitant to the observed phenomena in angiogenesis. By contrast, the anti-tumor and anti-angiogenic effects of ginsenosides (e.g. Rg3 and Rh2) have been demonstrated in various models of tumor and endothelial cells, indicating that ginsenosides with opposing activities are present in ginseng. Ginsenosides and Panax ginseng extracts have been shown to exert protective effects on vascular dysfunctions, such as hypertension, atherosclerotic disorders and ischemic injury. Recent work has demonstrates the target molecules of ginsenosides to be a group of nuclear steroid hormone receptors. These lines of evidence support that the interaction between ginsenosides and various nuclear steroid hormone receptors may explain the diverse pharmacological activities of ginseng. These findings may also lead to development of more efficacious ginseng-derived therapeutics for angiogenesis-related diseases.      </description>
			<link>http://www.cmjournal.org/content/2/1/6</link>		
			<dc:creator>Patrick Ying Kit Yue, Nai Ki Mak, Yuen Kit Cheng, Kar Wah Leung, Tzi Bun Ng, David Tai Ping Fan, Hin Wing Yeung and Ricky Ngok Shun Wong</dc:creator>
			<dc:source>Chinese Medicine 2007, 2:6</dc:source>
			<dc:subject>Number of accesses: 565</dc:subject>
			<dc:date>2007-05-15</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-2-6</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>2</prism:volume>
					
			
							
					<prism:startingPage>6</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-05-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/1/1/4">
            
            <title>Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials</title>
			<description>Extracts of Chinese red yeast rice (RYR, a traditional dietary seasoning of Monascus purpureus) contains several active ingredients including lovastatin, and several trials of its possible lipid-lowering effects have been conducted. This meta-analysis assesses the effectiveness and safety of RYR preparations on lipid modification in primary hyperlipidemia. We included randomized controlled trials testing RYR preparation, compared with placebo, no treatment, statins, or other active lipid-lowering agents in people with hyperlipidemia through searching PubMed, CBMdisk, TCMLARS, the Cochrane Library, and AMED up to December 2004. Ninety-three randomized trials (9625 participants) were included and three RYR preparations (Cholestin, Xuezhikang and Zhibituo) were tested. The methodological quality of trial reports was generally low in terms of generation of the allocation sequence, allocation concealment, blinding, and intention-to-treat. The combined results showed significant reduction of serum total cholesterol levels (weighted mean difference -0.91 mmol/L, 95% confidence interval -1.12 to -0.71), triglycerides levels (-0.41 mmol/L, -0.6 to -0.22), and LDL-cholesterol levels (-0.73 mmol/L, -1.02 to -0.043), and increase of HDL-cholesterol levels (0.15 mmol/L, 0.09 to 0.22) by RYR treatment compared with placebo. The lipid modification effects appeared to be similar to pravastatin, simvastatin, lovastatin, atorvastatin, or fluvastatin. Compared with non-statin lipid lowering agents, RYR preparations appeared superior to nicotinate and fish oils, but equal to or less effective than fenofibrate and gemfibrozil. No significant difference in lipid profile was found between Xuezhikang and Zhibituo. RYR preparations were associated with non-serious adverse effects such as dizziness and gastrointestinal discomfort. Current evidence shows short-term beneficial effects of RYR preparations on lipid modification. More rigorous trials are needed, and long-term effects and safety should be investigated if RYR preparations are to be recommended as one of the alternative treatments for primary hyperlipidemia.</description>
			<link>http://www.cmjournal.org/content/1/1/4</link>		
			<dc:creator>Jianping Liu, Jing Zhang, Yi Shi, Sameline Grimsgaard, Terje Alraek and Vinjar F&#248;nneb&#248;</dc:creator>
			<dc:source>Chinese Medicine 2006, 1:4</dc:source>
			<dc:subject>Number of accesses: 479</dc:subject>
			<dc:date>2006-11-23</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-1-4</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>1</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2006-11-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/2/1/11">
            
            <title>American ginseng modulates pancreatic beta cell activities</title>
			<description>The mechanism of the beneficial effects of Panax quinquefolius (Xiyangshen, American ginseng) on diabetes is yet to be elucidated. Recent studies show that Panax quinquefolius increases insulin production and reduces the death of pancreatic beta cells. Mechanism studies indicate that Panax quinquefolius improves cell's immuno-reactivity and mitochondrial function through various factors. Clinical studies show that Panax quinquefolius improves postprandial glycemia in type 2 diabetic patients. Further studies to identify the component(s) of Panax quinquefolius linked with pancreatic islets/beta cells in vitro and in vivo are warranted for better understanding of the full effects of Panax quinquefolius.</description>
			<link>http://www.cmjournal.org/content/2/1/11</link>		
			<dc:creator>Zonggui Wu, John Zeqi Luo and Luguang Luo</dc:creator>
			<dc:source>Chinese Medicine 2007, 2:11</dc:source>
			<dc:subject>Number of accesses: 402</dc:subject>
			<dc:date>2007-10-25</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-2-11</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>2</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-10-25</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/2/1/5">
            
            <title>A survey of Chinese herbal ingredients with liver protection activities</title>
			<description>A literature survey was conducted on herbs, their preparations and ingredients with reported liver protection activities, in which a total of 274 different species and hundreds of active ingredients have been examined. These ingredients can be roughly classified into two categories according to their activities: (1) the main ingredients, such as silybin, osthole, coumarin, glycyrrhizin, saikosaponin A, schisandrin A, flavonoids; and (2) supporting substances, such as sugars, amino acids, resins, tannins and volatile oil. Among them, some active ingredients have hepatoprotective activities (e.g. anti-inflammatory, anticancer, antioxidant, immunomodulating and liver cirrhosis-regulating effects). Calculation of physicochemical parameters indicates that the main ingredients with negative and positive Elumo values possibly display their hepatoprotective effects through different mechanisms, such as antioxidative, anti-inflammatory and immunomodulating effects. As the combination of herbs may achieve some treatment effects synergistically and/or additively, it is common in Chinese medicine to use mixtures of various medicinal herbs with pharmacologically active compounds to have synergistic and/or additive effects, or to reduce harmful effects of some pharmacologically active compounds. In particular, the active compounds with Clog P around 2 are suitable for passive transport across membranes and accessible to the target sites. Thus, Elumo and Clog P values are good indicators among the calculated parameters.Seven different physicochemical parameters (MW, Clog P, CMR, &#956;, Ehomo, Elumo and Hf) and four major biological activities (antioxidant, anti-inflammatory, antiviral/antitumor and immunomodulating) are discussed in this review. It is hoped that the discussion may provide some leads in the development of new hepatoprotective drugs.</description>
			<link>http://www.cmjournal.org/content/2/1/5</link>		
			<dc:creator>Rubin Wang, John Kong, Dali Wang, Linda Lin-min Lien and Eric Jung-chi Lien</dc:creator>
			<dc:source>Chinese Medicine 2007, 2:5</dc:source>
			<dc:subject>Number of accesses: 342</dc:subject>
			<dc:date>2007-05-10</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-2-5</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>2</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-05-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/3">
            
            <title>Metabolic profiling reveals therapeutic effects of Herba Cistanches in an animal model of hydrocortisone-induced 'kidney-deficiency syndrome'</title>
			<description>Background:
Herba Cistanches (Roucongrong) is effective in treating Shenxu Zheng ('kidney-deficiency syndrome'). However, the mechanisms and systemic metabolic responses to the herbal intervention are unclear.
Methods:
Using GC-MS-based metabolic profiling, we investigated the metabolic responses to Herba Cistanches intervention in a rat model of the hydrocortisone-induced 'kidney-deficiency syndrome'.
Results:
The metabolic profiles of the rats after hydrocortisone injection deviated from the pre-dose metabolic state at different time points, ranging from day 1 to day 10, whereas the metabolic profiles of the rats treated with both hydrocortisone and water extract of Herba Cistanches returned to the pre-dose state on day 10.
Conclusion:
The intervention of Herba Cistanches caused a systemic recovery from the hydrocortisone-induced metabolic perturbation in rats. This study also demonstrates that metabolic profiling is useful in studying therapeutic mechanisms of herbal medicines.</description>
			<link>http://www.cmjournal.org/content/3/1/3</link>		
			<dc:creator>Yunping Qiu, Minjun Chen, Mingming Su, Guoxiang Xie, Xin Li, Mingmei Zhou, Aihua Zhao, Jian Jiang and Wei Jia</dc:creator>
			<dc:source>Chinese Medicine 2008, 3:3</dc:source>
			<dc:subject>Number of accesses: 340</dc:subject>
			<dc:date>2008-03-10</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-3</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>3</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-03-10</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/5">
            
            <title>Simultaneous determination of eight major bioactive compounds in Dachengqi Tang (DT) by high-performance liquid chromatography</title>
			<description>Background:
Dachengqi Tang (DT) is a common traditional Chinese medicine formula for expelling neire ('internal heat') in the stomach and intestines. There was no reliable analytical method available for the quality control of DT.
Methods:
A high-performance liquid chromatography (HPLC) method with a reverse phase C18 column (150 &#215; 4.6 mm) was developed. The mobile phase was methanol with 0.2% acetic acid. Eight markers including naringin, hesperidin, aloe emodin, rhein, honokiol, magnolol, emodin and chrysophanol were determined.
Results:
Regression analysis revealed a linear relationship between the concentrations of the markers and the peak area ratio of the standards and internal standard. The limit of detection (S/N = 3) and the limit of qualification (RSD &lt; 20%) ranged from 0.21 to 0.43 ng/&#956;l and 0.76 to 1.74 ng/&#956;l respectively. The recovery was between 95.6% and 103.4%. The tests on the samples from three batches of DT showed that the profiles of the markers did not vary significantly among batches.
Conclusion:
A reliable HPLC method for simultaneous determination of the eight markers in DT was developed.</description>
			<link>http://www.cmjournal.org/content/3/1/5</link>		
			<dc:creator>Wenfu Tang, Meihua Wan, Zhengyan Zhu, Guanyuan Chen and Xi Huang</dc:creator>
			<dc:source>Chinese Medicine 2008, 3:5</dc:source>
			<dc:subject>Number of accesses: 314</dc:subject>
			<dc:date>2008-04-29</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-5</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-29</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.cmjournal.org/content/3/1/8">
            
            <title>Effects of ginsenosides Re and Rg3 on intracellular redox state and cell proliferation in C6 glioma cells</title>
			<description>Background Cellular redox state is important to cell growth and death. The growth of tumor cells may be modulated by intracellular reduced glutathione / oxidized glutathione (GSH/GSSG). The present study aims to investigate the effects of ginsenosides Re and Rg3 on cellular redox state and cell proliferation in C6 glioma cells. Methods Cultured C6 glioma cells were exposed to various concentrations of either Rg3 or Re for 24 hours. Cell growth and death were measured by the BrdU incorporation assay and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay respectively. Cellular redox state was determined by free radical production using flow cytometry and GSH/GSSG using spectrofluorometry. Results At a sub-lethal concentration, Re suppressed cell proliferation with a significant decrease in BrdU incorporation. Re did not increase reactive oxygen species (ROS) production but increased GSH/GSSG via increased activity of gamma glutamylcystenyl synthase (gamma-GCS). In contrast, Rg3 increased free radical production and reduced GSH/GSSG. The effects of Rg3 were probably due to increased activity of glutathione peroxidase (GPx). Conclusion Re and Rg3 alter cellular redox state of C6 glioma cells in opposite directions. Changes in cellular redox state induced by Re and Rg3 are correlated with the proliferation rates of C6 glioma cells.</description>
			<link>http://www.cmjournal.org/content/3/1/8</link>		
			<dc:creator>Wai Yee Ng and Mildred S Yang</dc:creator>
			<dc:source>Chinese Medicine 2008, 3:8</dc:source>
			<dc:subject>Number of accesses: 299</dc:subject>
			<dc:date>2008-07-11</dc:date>
			<dc:identifier>doi:10.1186/1749-8546-3-8</dc:identifier>
			
			
							
					<prism:publicationName>Chinese Medicine</prism:publicationName>
					
			
							
					<prism:issn>1749-8546</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>8</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
